Last updated 29 days ago

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

245 patients around the world

Available in Spain, Chile

Hoffmann-La Roche

1Research sites

245Patients around the world

This study is for people with

Alzheimer disease

Requirements for the patient

To 85 Years

All Gender

Medical requirements

Sites

Centro de Investigaciones Clínicas UC - CICUC

Recruiting

Santiago, Santiago Metropolitan Region, Chile

SponsorHoffmann-La Roche

Conditions

Alzheimer disease

Requirements

To 85 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06402838